Barnini Ghosh: Neoadjuvant Versus Adjuvant Immunotherapy in MSI-H/dMMR Early Colorectal Cancer
Barnini Ghosh/rubyhospital.com

Barnini Ghosh: Neoadjuvant Versus Adjuvant Immunotherapy in MSI-H/dMMR Early Colorectal Cancer

Barnini Ghosh, Consultant Medical Oncologist at Ruby General Hospital, shared a post on LinkedIn:

“With immense pleasure, I share our latest publication – “Neoadjuvant versus Adjuvant Immunotherapy in MSI-H/dMMR Early Colorectal Cancer: A Value-Conscious Re-examination of Dogma,” published in the Indian Journal of Medical and Paediatric Oncology (IJMPO), written under the guidance of Dr. Amol Akhade, one of the most esteemed and highly reputed experts in the field of Medical Oncology.

This perspective highlights the critical nuances of timing immunotherapy, challenging the existing paradigms to promote value-conscious, effective care for patients with early colorectal cancer.

Deeply grateful for this opportunity for collaboration and learning.”

Title: Neoadjuvant versus Adjuvant Immunotherapy in MSI-H/dMMR Early Colorectal Cancer: A Value-Conscious Re-examination of Dogma

Author: Barnini Ghosh, Amol Akhade

Read the Full Article.

Barnini Ghosh: Neoadjuvant Versus Adjuvant Immunotherapy in MSI-H/dMMR Early Colorectal Cancer